메뉴 건너뛰기
Drug News and Perspectives
Volumn 22, Issue 9, 2009, Pages 559-567
The role of incretin-based therapies in the management of type 2 diabetes
Author keywords

[No Author keywords available]
Indexed keywords

6,7 DICHLORO 2 METHYLSULFONYL 3 N TERT BUTYLAMINOQUINOXALINE; ALBIGLUTIDE; ALOGLIPTIN; ANTIDIABETIC AGENT; AVE 0010; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; LY 2189265; METFORMIN; PIOGLITAZONE; PLACEBO; QUINOXALINE DERIVATIVE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;
EID: 76749086582     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2009.22.9.1437963     Document Type: Conference Paper
Times cited : (2)
References (79)
  • 1
    • 0028817815 scopus 로고    scopus 로고
    • [No authors listed]. U.K. Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: A progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995, 44(11): 1249-58.
    • [No authors listed]. U.K. Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: A progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995, 44(11): 1249-58.
  • 2
    • 38149057538 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Update regarding thiazolidinediones: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
    • Nathan, D.M., Buse, J.B., Davidson, M.B., Ferrannini, E., Holman, R.R., Sherwin, R., and Zinman, B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Update regarding thiazolidinediones: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008, 31: 173-75.
    • (2008) Diabetes Care , vol.31 , pp. 173-175
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3    Ferrannini, E.4    Holman, R.R.5    Sherwin, R.6    Zinman, B.7
  • 3
    • 76749160175 scopus 로고    scopus 로고
    • Marks, V. and Morgan, L. The entero-insular axis in recent advances in diabetes, 1 Nattrass, M., Santiago (eds) Churchill Livingstone, London 1984, 1: 55-71.
    • Marks, V. and Morgan, L. The entero-insular axis in recent advances in diabetes, vol 1 Nattrass, M., Santiago (eds) Churchill Livingstone, London 1984, 1: 55-71.
  • 4
    • 0022617246 scopus 로고
    • Reduced incretin effecting Type 2 (non-insulin-dependent) diabetes
    • Nauck, M., Stöckmann, F., Ebert, R. and Creuzfeldt, W. Reduced incretin effecting Type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29(1): 46-52.
    • (1986) Diabetologia , vol.29 , Issue.1 , pp. 46-52
    • Nauck, M.1    Stöckmann, F.2    Ebert, R.3    Creuzfeldt, W.4
  • 5
    • 0027391607 scopus 로고
    • Preserved incretin activity of glucogon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus
    • Nauck, M.A., Heimesaat, M.M., Orskov, C., Holst, J.J., Ebert, R. and Creutzfeldt, W. Preserved incretin activity of glucogon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 1993, 91(1): 301-7.
    • (1993) J Clin Invest , vol.91 , Issue.1 , pp. 301-307
    • Nauck, M.A.1    Heimesaat, M.M.2    Orskov, C.3    Holst, J.J.4    Ebert, R.5    Creutzfeldt, W.6
  • 8
    • 76749090441 scopus 로고    scopus 로고
    • No enhancement of meal-induced GLP-1 secretion and reduced intact GLP-1 levels in Japanese patients with type 2 diabetes as well as healthy controls
    • September 29-October 2, Vienna, Abst 793
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 793.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Yabe, D.1    Kuroe, A.2    Lee, S.3
  • 9
    • 85055199489 scopus 로고    scopus 로고
    • A pilot study examining the effect of GLP1R polymorphisms on insulin secretion in response to glucose and GLP-1 infusion in non-diabetic subjects
    • September 29-October 2, Vienna, Abst 127
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 127.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Vella, A.1    Sathananthan, A.2    Micheletto, F.3
  • 11
    • 76749106904 scopus 로고    scopus 로고
    • Impact of endogenous and exogenous GLP-1 on glucagon secretion in type 1 diabetic patients with and without residual beta-cell function
    • September 29-October 2, Vienna, Abst 128
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 128.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Kielgast, U.1    Madsbad, S.2    Holst, J.3
  • 15
    • 76749155324 scopus 로고    scopus 로고
    • The once-daily human GLP-1 analogue liraglutide increases the beta cell mass in normoglycemic mice by directly accelerating cell differentiation and proliferation
    • September 29-October 2, Vienna, Abst 68
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 68.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Shimoda, M.1
  • 19
    • 76749107373 scopus 로고    scopus 로고
    • Metabolic and insulin resistance-related indices during pioglitazone and vildagliptin association versus glimepiride and vildagliptin association in type 2 diabetic patients
    • September 29-October 2, Vienna, Abst 799
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 799.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Fogari, R.1    Cicero, A.2    Ragonesi, P.3
  • 26
    • 76749086884 scopus 로고    scopus 로고
    • Reductions in glycaemia and weight with once-weekly dosing of LY2189265, a long-acting glucagon-like peptide 1 (GLP-1) analogue in patients with type 2 diabetes mellitus
    • September 29-October 2, Vienna, Abst 731
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl .1): Abst 731.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. .1
    • Hardy, T.A.1    Barrington, P.2    Chien, J.3
  • 28
    • 76749116051 scopus 로고    scopus 로고
    • One-year exenatide treatment improves beta cell response in metformin treated patients with type 2 diabetes which is sustained after 5 weeks discontinuation of treatment
    • September 29-October 2, Vienna, Abst 1
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 1.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Bunck, M.C.1    Mari, A.2    Corner, A.3
  • 29
    • 70450199755 scopus 로고    scopus 로고
    • Exenatide compared with long acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes mellitus: Results of the Helping Evaluate Exenatide in patients with diabetes compared to Long-Acting insulin (HEELA) study
    • September 29-October 2, Vienna, Abst 738
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 738.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Davies, M.J.1    Donnelly, R.2    Barnett, A.H.3    Jones, S.4    Nicolay, A.5    Kilcoyne, A.6
  • 32
    • 76749126955 scopus 로고    scopus 로고
    • DURATION 2: Weight-related quality of life, psychological well-being, and satisfaction with exenatide once weekly compared to sitagliptin or pioglitazone after 26 weeks of treatment
    • September 29-October 2, Vienna, Abst 745
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 745.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Best, J.H.1    Yan, P.2    Malloy, J.3
  • 34
    • 72449158329 scopus 로고    scopus 로고
    • Long-term sustained glycaemic control with liraglutide and glimepiride (both plus metformin), with added benefits of weight loss and less hypoglycaemia with liraglutide: 2-Year LEAD-2 data
    • September 29-October 2, Vienna, Abst 3
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 3.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Frid, A.1    Hermansen, K.2    Nauck, M.3
  • 35
  • 37
    • 76749150816 scopus 로고    scopus 로고
    • The human GLP-1 analogue liraglutide given once daily provides excellent metabolic control in Japanese patients either as monotherapy or in combination with SU during 52 weeks of treatment
    • September 29-October 2, Vienna, Abst 744
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 744.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Seino, Y.1    Rasmussen, M.F.2    Katayama, Y.3    Kaku, K.4
  • 46
    • 76749095769 scopus 로고    scopus 로고
    • Initial combination therapy with sitagliptin and pioglitazone improves glycaemic control and measures of beta cell function compared with pioglitazone alone in patients with type 2 diabetes
    • September 29-October 2, Vienna, Abst 747
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 747.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Yoon, K.1    Shockey, G.2    Teng, R.3
  • 48
    • 76749101488 scopus 로고    scopus 로고
    • Vildagliptin added to basal insulin glargine improves glycaemic control and reduces glycaemic excursions in type 2 diabetes
    • September 29-October 2, Vienna, Abst 750
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 750.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Brooks, J.1    Bravis, V.2    Morgenstern, S.3
  • 53
    • 76749139375 scopus 로고    scopus 로고
    • Chronic administration of the glucagon-like peptide-1 analogue, liraglutide, delays diabetes onset and improves lipids in a novel model of type 2 diabetes, the UCD-T2DM rat
    • September 29-October 2, Vienna, Abst 784
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 784.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Havel, P.J.1    Cummings, B.P.2    Graham, J.L.3
  • 59
    • 76749125235 scopus 로고    scopus 로고
    • Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance under high-fat diet in mice
    • September 29-October 2, Vienna, Abst 785
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 785.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Liu, X.1    Harada, N.2    Yamane, S.3
  • 67
    • 70450150886 scopus 로고    scopus 로고
    • Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes
    • September 29-October 2, Vienna, Abst 762
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 762.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Plutzky, J.1    Garber, A.2    Toft, A.D.3    Poulter, N.R.4
  • 77
    • 76749162187 scopus 로고    scopus 로고
    • Safety and tolerability of exenatide BID in patients with type 2 diabetes: Integrated analysis of 3854 patients from 11 comparator controlled clinical trials
    • September 29-October 2, Vienna, Abst 768
    • th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 768.
    • (2009) th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Wintle, M.1    Bruce, S.2    MacConell, L.3
  • 78
    • 76749144037 scopus 로고    scopus 로고
    • Exenatide significantly ameliorates increases in pancreatic enzyme secretion in a rat model of acute pancreatitis
    • September 29-October 2, Vienna, Abst 771
    • Parkes, D., Adams, L., Lu, M. et al. Exenatide significantly ameliorates increases in pancreatic enzyme secretion in a rat model of acute pancreatitis. Diabetologia [45th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 771.
    • (2009) Diabetologia [45th Annu Meet Eur Assoc Study Diabetes (EASD) , vol.52 , Issue.SUPPL. 1
    • Parkes, D.1    Adams, L.2    Lu, M.3
  • 79
    • 76749101487 scopus 로고    scopus 로고
    • Bloomgren, G., Dore, D., Patterson, R., Noel, R., Braun and D. and Seeger, J. Incidence of acute pancreatitis in exenatide initiators compared to other antidiabetic drug initiators: A retrospective, cohort study. Diabetologia [45th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 6.
    • Bloomgren, G., Dore, D., Patterson, R., Noel, R., Braun and D. and Seeger, J. Incidence of acute pancreatitis in exenatide initiators compared to other antidiabetic drug initiators: A retrospective, cohort study. Diabetologia [45th Annu Meet Eur Assoc Study Diabetes (EASD) (September 29-October 2, Vienna) 2009] 2009, 52(Suppl. 1): Abst 6.

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.